In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

SAN DIEGO -- A 1-mg dose of semaglutide (Wegovy) weekly was better at maintaining weight than 3-mg liraglutide (Saxenda) daily for patients who put on pounds after bariatric surgery, a retrospective ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed ...

New research reveals that liraglutide, a GLP-1 receptor agonist, crosses the blood-brain barrier to target specific neurons, reducing appetite and promoting lasting weight loss. Liraglutide, a ...

In recent years, diabetes advocacy groups have called for greater attention to measures beyond glycated hemoglobin when evaluating diabetes drugs, because avoiding hypoglycemia and spending more time ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight Reduction ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it ...

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 ...